Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry

Journal of Medicinal Chemistry

Volumn 54, Issue 3, 2011, Pages 765-781

  Yermolina, Maria V ^a   Wang, Jizhen ^a   Caffrey, Michael ^a   Rong, Lijun L ^a   Wardrop, Duncan J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (DIETHYLAMINO) N [[3 (4 METHOXYPHENYL)ISOXAZOL 5 YL]METHYL]ETHANAMIDE; GLYCOPROTEIN; ISOXAZOLE DERIVATIVE; LUCIFERASE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SYNTHESIS; EBOLA VIRUS; FILOVIRUS; FILOVIRUS INFECTION; IC 50; MARBURG VIRUS; NONHUMAN; PSEUDOTYPING; REPORTER GENE; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; VIRUS ENTRY;

ANTIVIRAL AGENTS; CELL LINE; CLICK CHEMISTRY; EBOLAVIRUS; HUMANS; ISOXAZOLES; MARBURGVIRUS; SMALL MOLECULE LIBRARIES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; VIRAL ENVELOPE PROTEINS; VIROLOGY; VIRUS INTERNALIZATION;

EID: 79851503096     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1008715     Document Type: Article

References (52)

1. (a) Sanchez, A.; Geisbert, T. W.; Feldmann, H. Filoviridae: Marburg and Ebola viruses. In Fields Virology; Knipe, D.M., Howley, P., M., Griffin, D. E., Lamb, R. A., Martin, M. A., Eds.; Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, PA, 2007; pp 1409-1448.
2. (b)Hoenen, T.;Groseth,A.; Falzarano, D.; Feldmann,H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol. Med. 2006, 12, 206-215. (Pubitemid 43728410)
3. (c) Ascenzi, P.; Bocedi, A.; Heptonstall, J.; Capobianchi, M. R.; Di Antonino, C.; Mastrangelo, E.; Bolognesi,M.; Ippolito, G. Ebolavirus and marburgvirus: Insight the Filoviridae family. Mol. Aspects Med. 2008, 29, 151-185.
4. Leroy, E. M.; Rouquet, P.; Formenty, P.; Souquiere, S.; Kilbourne, A.; Froment, J. M.; Bermejo, M.; Smit, S.; Karesh, W.; Swanepoel, R.; Zaki, S. R.; Rollin, P. E. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004, 303, 387-390. (Pubitemid 38095781)
5. (a) Reed, D. S.; Mohamadzadeh, M. Status and challenges of filovirus vaccines. Vaccine 2007, 25, 1923-1934. (Pubitemid 46227672)
6. (b) Jones, S. M.; Feldmann, H.; Stroher, U.; Geisbert, J. B.; Fernando, L.; Grolla, A.; Klenk, H. D.; Sullivan, N. J.; Volchkov, V. E.; Fritz, E. A.; Daddario, K. M.; Hensley, L. E.; Jahrling, P. B.; Geisbert, T. W. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Med. 2005, 11, 786-790. (Pubitemid 41021212)
7. (c) Kobinger, G. P.; Feldmann, H.; Zhi, Y.; Schumer, G.; Gao, G.; Feldmann, F.; Jones, S.; Wilson, J. M. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006, 346, 394-401. (Pubitemid 43357883)
8. Takada, A.; Ebihara, H.; Jones, S.; Feldmann, H.; Kawaoka, Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2007, 25, 993-999. (Pubitemid 44937459)
9. (a) Bray, M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003, 57, 53-60. (Pubitemid 36254721)
10. (b) Burnett, J. C.; Henchal, E. A.; Schmaljohn, A. L.; Bavari, S. The evolving field of biodefence: therapeutic developments and diagnostics. Nature Rev. Drug Discovery 2005, 4, 281-297. (Pubitemid 41135787)
11. (a) Bray, M.; Paragas, J. Experimental therapy of filovirus infections. Antiviral Res. 2002, 54, 1-17. (Pubitemid 34219170)
12. (b) Hensley, L. E.; Jones, S. M.; Feldmann, H.; Jahrling, P. B.; Geisbert, T. W. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr. Mol. Med. 2005, 5, 761-772. (Pubitemid 43009516)
13. (c) Stroher, U.; Feldmann, H. Progress towards the treatment of ebola haemorrhagic fever. Expert Opin. Invest. Drugs 2006, 15, 1523-1535. (Pubitemid 44848976)
14. Tseng, C. K. H.; Marquez, V. E.; Fuller, R. W.; Goldstein, B. M.; Haines, D. R.; McPherson, H.; Parsons, J. L.; Shannon, W. M.; Arnett, G.; Hollingshead, M.; Driscoll, J. S. Synthesis of 3-deazaneplanocin-A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J. Med. Chem. 1989, 32, 1442-1446. (Pubitemid 19205346)
15. Huggins, J.; Zhang, Z. X.; Bray, M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit ebola virus in vitro and in a lethal mouse model. J. Infect. Dis 1999, 179, S240-S247. (Pubitemid 29091408)
16. Schneller, S. W.; Yang, M. S-Adenosylhomocysteine hydrolase inhibitors as a source of anti-filovirus agents. In Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats; Torrence, P. F., Ed.; Wiley-Interscience: Hoboken, NJ, 2005; pp 139-152.
17. Bray, M.; Raymond, J. L.; Geisbert, T.; Baker, R. O. 3-Deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res. 2002, 55, 151-159. (Pubitemid 34655650)
18. Bray, M. Filoviridae. Filoviridae. In Clinical Virology; Richman, D. R., Whitley, R. J., Hayden, F. G., Eds.;ASMPress:Washington, DC, 2002; pp 875-890.
19. Pokrovskii, A. G.; Belanov, E. F.; Volkov, G. N.; Pliasunova, O. A.; Tolstikov, G. A.; Hoever, G.; Baltina, L.; Michaelis, M.; Kondratenko, R.; Baltina, L.; Tolstikov, G. A.; Doerr, H. W.; Cinatl, J., Jr.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H. W. Inhibition of Marburg virus reproduction by glycyrrhizinic acid and its derivatives. Dokl. Chem. 1995, 344, 709-711.
20. Mayaux, J. F.; Bousseau, A.; Pauwels, R.; Huet, T.; Henin, Y.; Dereu, N.; Evers, M.; Soler, F.; Poujade, C.; Declercq, E.; Lepecq, J. B. Triterpene derivatives that block entry of human-immunodeficiency-virus type-1 into cells. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3564-3568. (Pubitemid 24139470)
21. Geisbert, T. W.; Jahrling, P. B. Differentiation of filoviruses by electron microscopy. Virus Res. 1995, 39, 129-150. (Pubitemid 26054781)
22. Yonezawa, A.; Cavrois, M.; Greene, W. C. Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J. Virol. 2005, 79, 918-926. (Pubitemid 40053875)
23. Bar, S.; Takada, A.; Kawaoka, Y.; Alizon, M. Tyro3 familymediated cell entry of ebola and marburg viruses. J. Virol. 2006, 80, 2815-2822.
24. Chan, S. Y.; Speck, R. F.; Ma, M. C.; Goldsmith, M. A. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Virol. 2000, 74, 4933-4937. (Pubitemid 30237927)
25. Chandran,K.; Sullivan,N. J.;Felbor,U.;Whelan, S.P.;Cunningham, J. M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005, 308, 1643-1645. (Pubitemid 40807517)
26. Schornberg, K.; Matsuyama, S.; Kabsch, K.; Delos, S.; Bouton, A.; White, J. Role of endosomal cathepsins in entry mediated by the ebola virus glycoprotein. J. Virol. 2006, 80, 4174-4178.
27. Hanewinkel, H.; Glossl, J.; Kresse, H. Biosynthesis of cathepsin B in cultured normal and I-cell fibroblasts. J. Biol. Chem. 1987, 262, 12351-12355.
28. Jane-Valbuena, J.; Breun, L. A.; Schiff, L. A.; Nibert, M. L. Sites and determinants of early cleavages in the proteolytic processing pathway of reovirus surface protein s3. J. Virol. 2002, 76, 5184-5197. (Pubitemid 34441722)
29. Kolokoltsov, A. A.; Saeed, M. F.; Freiberg, A. N.; Holbrook, M. R.; Davey, R. A. Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening. Drug Dev. Res. 2009, 70, 255-265.
30. 2+ calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem. Biophys. Res. Commun. 1991, 181, 968-975.
31. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylnositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269, 5241-5248.
32. (a) For overviews of pseudotyped viral vectors, see: (a) Ames, R. S.; Lu, Q. Viral-mediated gene delivery for cell-based assays in drug discovery. Expert. Opin. Drug Discovery 2009, 4, 243-256.
33. Bouard, D.; Alazard-Dany, N.; Cosset, F. L. Viral vectors: From virology to transgene expression. Br. J. Pharmacol. 2009, 157, 153-165.
34. Takada, A.; Robison, C.; Goto, H.; Sanchez, A.; Murti, K. G.; Whitt, M. A.; Kawaoka, Y. A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14764-14769. (Pubitemid 28041448)
35. Wool-Lewis, R. J.; Bates, P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol. 1998, 72, 3155-3160. (Pubitemid 28175558)
36. Manicassamy, B.; Wang, J.; Jiang, H.; Rong, L. Comprehensive analysis of Ebola virus GP1 in viral entry. J. Virol. 2005, 79, 4793-4805. (Pubitemid 40464230)
37. For recent examples of this approach, published during the course of our studies, see refs 22 and 30.
38. The rhodanine derivative LJ001 has been found to target the lipid membrane of a wide range of enveloped viruses, including Ebola, Marburg and vesticular stomatis, and comprises their ability to mediate virus-cell fusion: Wolf, M. C.; Freiberg, A. N.; Zhang, T. H.; Akyol-Ataman, Z.; Grock, A.; Hong, P. W.; Li, J. R.; Watson, N. F.; Fang, A. Q.; Aguilar, H. C.; Porotto, M.; Honko, A.N.; Damoiseaux, R.;Miller, J. P.;Woodson, S. E.; Chantasirivisal, S.; Fontanes,V.;Negrete, O. A.;Krogstad, P.;Dasgupta, A.;Moscona, A.; Hensley, L. E.; Whelan, S. P.; Faull, K. F.; Holbrook, M. R.; Jung, M. E.; Lee, B. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 3157-3162.
39. Hansen, T. V.; Wu, P.; Fokin, V. V. One-pot copper(I)-catalyzed synthesis of 3,5-disubstituted isoxazoles. J. Org. Chem. 2005, 70, 7761-7764. (Pubitemid 41318540)
40. Quan, C.; Kurth, M. Solid-phase synthesis of 5-isoxazol-4-yl-[1,2,4] oxadiazoles. J. Org. Chem. 2004, 69, 1470-1474. (Pubitemid 38280389)
41. Hassner, A.; Rai, K. Synthetic methods. 29. A new method for the generation of nitrile oxides and its application to the synthesis of 2-isoxazolines. Synthesis 1989, 57-59.
42. Grünanger, P.; Vita-Finzi, P.; Dowling, J. E. Isoxazoles; Wiley: New York, 1991; pp 183-196.
43. Katsura, Y.; Nishino, S.; Inoue, Y.; Sakane, K.; Matsumoto, Y.; Morinaga, C.; Ishikawa, H.; Takasugi, H. Anti-Helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues. J. Med. Chem. 2002, 45, 143-150. (Pubitemid 34038549)
44. Himo, F.; Lovell, T.; Hilgraf, R.; Rostovtsev, V. V.; Noodleman, L.; Sharpless, K. B.; Fokin, V. V. Copper(I)-Catalyzed Synthesis of Azoles. DFT Study Predicts Unprecedented Reactivity and Intermediates. J. Am. Chem. Soc. 2005, 127, 210-216. (Pubitemid 40094384)
45. (a) He, J.; Choe, S.; Walker, R.; Di Marzio, P.; Morgan, D. O.; Landau, N. R. Human-immunodeficiency-virus type-1 viral-protein-r (vpr) arrests cells in the g(2) phase of the cellcycle by inhibiting p34(cdc2) activity. J. Virol. 1995, 69, 6705-6711.
46. Connor, R. I.; Chen, B. K.; Choe, S.; Landau, N. R. Vpr is required for efficient replication of human-immunodeficiency-virus type-1 in mononuclear phagocytes. Virology 1995, 206, 935-944.
47. Cleij, M. C.; Scrimin, P.; Tecilla, P.; Tonellato, U. Efficient and highly selective copper(II) transport across a bulk liquid chloroform membrane mediated by lipophilic dipeptides. J. Org. Chem. 1997, 62, 5592-5599. (Pubitemid 127494911)
48. Valduga, C. J.; Santis, D. B.; Braibante, M. E. F. Reactivity of p-phenyl substituted beta-enamino compounds using K-10/ultrasound. II. Synthesis of isoxazoles and 5-isoxazolones. J. Heterocycl. Chem. 1999, 36, 505-508. (Pubitemid 29220965)
49. Shvekhgeimer, G. A.; Baranski, A.; Grzegozek, M. Reaction of benzonitrile oxides with conjugated nitroalkenes. Synthesis 1976, 612-614.
50. Wilson, J. A.; Hevey, M.; Bakken, R.; Guest, S.; Bray, M.; Schmaljohn, A. L.; Hart., M. K. Epitopes involved in antibodymediated protection from Ebola virus. Science 2000, 287, 1664-1666. (Pubitemid 30127770)
51. Simon, J. H.; Fouchier, R. A.; Southerling, T. E.; Guerra, C. B.; Grant, C. K.; Malim, M. H. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J. Virol. 2000, 71, 5259-5267.
52. Manicassamy, B.; Wang, J.; Rumschlag, E.; Tymen, S.; Volchkova, V.; Volchkov, V.; Rong, L. Characterization of Marburg virus glycoprotein in viral entry. Virology 2007, 358, 79-88. (Pubitemid 46061428)